BI 836880
Alternative Names: Anti-VEGF/Ang2 Nanobody®; BI-836880; Bi-specific Anti-VEGF/Ang2 Nanobody®; VEGF/Ang2 Nanobody ®Latest Information Update: 28 May 2025
At a glance
- Originator Ablynx
- Developer Boehringer Ingelheim
- Class Antineoplastics; Bispecific antibodies; Eye disorder therapies; Immunotherapies
- Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anal cancer; Solid tumours
- Phase I/II Wet age-related macular degeneration
- No development reported Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Squamous cell cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Nasopharyngeal-cancer in Germany (Intraperitoneal, Injection)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV, Infusion)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV, Infusion)